Supramolecular Assembly of Tetramethylcucurbit[6]uril and 2-Picolylamine

The supramolecular assembly of symmetrical tetramethylcucurbit[6]uril (TMeQ[6]) and 2-picolylamine (AMPy) has been investigated via various techniques, including ultraviolet-visible (UV-vis) and nuclear magnetic resonance spectroscopy, isothermal titration calorimetry (ITC), and X-ray crystallography. The results indicated that TMeQ[6] could encapsulate the AMPy guest molecule to form a stable inclusion complex. The rotational restriction of the guest in the cavity of TMeQ[6] resulted in a large negative value of entropy. The X-ray crystal structure of the 1:1 inclusion complex between TMeQ[6] and AMPy revealed that AMPy exists in the elliptical cavity of TMeQ[6]

Supramolecular assemblies of cucurbit[n]urils and 4-aminopyridine controlled by cucurbit[n]uril size (n = 5, 6, 7 and 8)

The binding interactions between 4-aminopyridine (4-AP) and a series of cucurbit[n]urils (Q[5], Q[6], TMeQ[6], Q[7], Q[8]) have been studied using 1H NMR spectroscopy, UV–vis absorption spectroscopy, isothermal titration calorimetry (ITC) and X-ray crystallography. The data indicates that the Q[5]@4-AP complex exhibits exo binding, which is not observed in the other four host-guest complexes. Furthermore, X-ray crystallography clearly reveals how the Q[n]s bind with 4-AP to form complexes, for example Q[5] forms an outer-surface complex, whilst Q[6], TMeQ[6] and Q[7] formed a 1:1 host and guest type complex, and Q[8] formed a stable 1:2 ternary complex due to its large cavity, which can accommodate two 4-AP molecules

Clinical observation on the therapeutic efficacy of mesenchymal stem cell-derived exosomes for rosacea

Objective To observe the therapeutic effects of mesenchymal stem cell-derived exosomes on rosacea. Methods Seventy-eight patients with rosacea, including 39 PPR type and 39 ETR type, were enrolled at the Changsha Mylike Cosmetic Hospital from January 2021 to January 2022. All patients were treated with microneedling infusion of mesenchymal stem cell-derived exosomes (MSC-exo) once a month for three months. The clinical efficacy, adverse reactions, erythema assessment scale (CEA), patient physical evaluation (PSA), investigators' global assessment (IGA) scale and skin barrier function were compared between the two groups. Results Treatment with MSC-exo significantly decreased both CEA and IGA scales, EI and TEWL, while increasing stratum corneum hydration (P<0.05 for all). After 3 treatments with MSC-exo, both CEA and IGA scales were higher in patients with ETR type than in that with PPR type (both P<0.05). Both EI and TEWL were lower in patients with PPR than in that with ETR (P<0.05). In contrast, both stratum corneum hydration levels and PSA were higher in patients with PPR than in that with ETR (P<0.05). The effective rates in patients with PPR type and ETR type were 89.74% and 64.10%, respectively (χ2=7.22, P=0.007). However, the adverse reaction rates were comparable between the two groups (χ2=1.92, P=0.166). Conclusions Treatments with MSC-exo can significantly improve the skin condition and skin barrier function in patients with rosacea. Compared with the ETR group, MSC-exo is more effective in improving skin condition in the PPR